NCT03819218View on ClinicalTrials.gov

A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects

PHASE2TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

December 11, 2020

Study Completion Date

December 11, 2020

Conditions

Psoriasis Vulgaris

Interventions

DRUG

MC2-01 cream

MC2-01 cream (Calcipotriene/betamethasone dipropionate, w/w 0.005%/ 0.064%)

Trial Locations (2)

60590

Dept. of Dermatology, Venereology and Allergology, Frankfurt

110 00

PRO SANUM a.s., Prague

Sponsors

Lead Sponsor

MC2 Therapeutics

All Listed Sponsors

lead

MC2 Therapeutics

INDUSTRY